Wednesday, October 14, 2026
Via News Knowledge File

Securities and Exchange Commission

government agency80% conf.·synced Oct 14, 2026

Federal regulatory agency overseeing securities markets

9
sourced metrics
1487
relationships
4
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Rias Over 75 Years Old
89companies
Jan 1, 2025source
Rias Registered Before 2018
7935companies
Jan 1, 2025source
Client Count
68400000clients
Jan 1, 2025source
Employee Count
1000000employees
Jan 1, 2025source
Assets Under Management
144.6trillion_USD
Jan 1, 2025⚠ sources conflictsource
Registered Rias
15870companies
Jan 1, 2025source
Rias Over 50 Years Old
124companies
Jan 1, 2025source
Registered Companies
436companies
Jan 1, 1940source
Account Count
300000accounts
Jan 1, 1940source

Stated objectives

Explore ways to allow 401(k) plan participants to have greater access to alternative assets

source
stated

Recover funds through SEC Whistleblower program; persons with non-public information regarding Coty may receive rewards up to 30% of any successful SEC recovery

source
target: 30 percent of successful recovery stated

Issue an innovation exemption allowing third-party tokenization of public company stocks without issuer consent

source
by 2026-05-23 00:00:00stated

Enable stock tokenization on blockchain through an innovation exemption, allowing 24/7 trading of equities including by third parties without company consent

source
stated

Relationship graph · 1487 connections

regulates
1242
regulated by
206
Employs
17
governs
7
files with
3
contracted by
2
allied with
2
employed by
2

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com